Anticoagulant Reversal Drugs Market

Industry Outlook

The global anticoagulant reversal drugs market is expected to grow at a compound annual growth rate (CAGR) of 15.3% during the forecast period from 2018 to 2026. Reversing the effects of anticoagulants, including novel oral anticoagulants (NOACs), vitamin K antagonists, and others, is a major concern in clinical practice, especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in the last decade have increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT).

However, this growth in anticoagulants’ usage has led to a rise in the incidence of hospital admissions and deaths due to increased bleeding due to anticoagulation. According to the Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in the U.S. alone, and close to 2,000 deaths per month were attributable to anticoagulation or factor Xa inhibitor-related bleeding. These factors have led to furious research and the development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted special status and accelerated approvals for the development and swift market entry of certain anticoagulant antidotes.

Market Synopsis

Recent Approval of the First Reversal Agent for Apixaban and Rivaroxaban Anticoagulants Will Drive the Market

In May 2018, the U.S. FDA approved Andexxa, the first factor Xa inhibitor reversal agent by Portola Pharmaceutical, Inc. The drug can act as an antidote for patients being treated with rivaroxaban (Xarelto) and apixaban (Eliquis) during uncontrolled bleeding and life-threatening situations by reversing anticoagulation effects. Andexxa received both orphan drug status and breakthrough drug designation by the U.S. FDA and has shown prominent clinical efficiency during clinical trials. Increased use of factor Xa inhibitors will drive the market for Andexxa, helping it grow at the fastest rate during the forecast period. Idarucizumab and Prothrombin Complex Concentrates also hold a significant share in the anticoagulant reversal drug market owing to the increased use of these agents during critical situations. Idarucizumab, which was approved in 2015, was the only drug that could reverse dabigatran etexilate mesylate’s anticoagulant effects.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments was calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The anticoagulant reversal drugs market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class and geography.

The market is studied in order to understand the current dynamics and future trends in the global anticoagulant reversal drug market. The study includes market size and forecasts for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rates (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year.

The key players currently engaged in the anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., Pfizer, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc., and Ferring Pharmaceuticals.

Key questions are answered in this report.

• How will the global market for anticoagulant reversal drugs perform during the forecast period from 2018 to 2026?
• What are the most recent trends in the anticoagulant reversal drug market, as well as the most promising opportunities for key players?
• Who are the leading players in the global anticoagulant reversal drug market?
• Which is the leading and fastest-growing region in the global anticoagulant reversal drug market?
• What are the drivers and restraints governing the global anticoagulant reversal drug market?
• What is the pipeline of anticoagulant reversal drugs on the market?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global ARD Market Portraiture
2.2. Global ARD Market, by Drug Class, 2017 (US$ Mn)
2.3. Global ARD Market, by Geography, 2017 (US$ Mn)

Chapter 3. Anticoagulant Reversal Drugs (ARD): Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global ARD Market, by Key Players, 2017

Chapter 4. Global Anticoagulant Reversal Drugs (ARD) Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Prothrombin Complex Concentrates (PCC)
4.3. Vitamin K
4.4. Protamine
4.5. Tranexmic Acid
4.6. Desmopressin
4.7. Idarucizumab
4.8. Andexxa
4.9. Pipeline Analysis
4.9.1. Phase III Drugs
4.9.1.1. Octaplex
4.9.2. Phase I and II Drugs (Tabular Representation)

Chapter 5. Global Anticoagulant Reversal Drugs (ARD) Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. North America ARD Market Analysis, 2016 – 2026
5.1.1. North America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.1.2. North America ARD Market, by Country, 2016 – 2026 (US$ Mn)
5.1.2.1. U.S.
5.1.2.2. Canada
5.2. Europe ARD Market Analysis, 2016 – 2026
5.2.1. Europe ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. Europe ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.2.2.1. U.K.
5.2.2.2. Germany
5.2.2.3. Rest of Europe
5.3. Asia Pacific ARD Market Analysis, 2016 – 2026
5.3.1. Asia Pacific ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Asia Pacific ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. China
5.3.2.2. Japan
5.3.2.3. Rest of Asia Pacific
5.4. Latin America ARD Market Analysis, 2016 – 2026
5.4.1. Latin America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Latin America ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. Brazil
5.4.2.2. Mexico
5.4.2.3. Rest of Latin America
5.5. Middle East & Africa ARD Market, 2016 – 2026
5.5.1. Middle East & Africa ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Middle East & Africa ARD Market, by Region, 2016 – 2026 (US$ Mn)
5.5.2.1. GCC
5.5.2.2. Rest of Middle East & Africa

Chapter 6. Company Profiles
6.1. Boehringer Ingelheim GmbH
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Fresenius Kabi AG
6.3. Pfizer, Inc.
6.4. Bausch Health Companies, Inc.
6.5. Amneal Pharmaceuticals, Inc.
6.6. CSL Behring Limited
6.7. Octapharma AG
6.8. Portola Pharmaceuticals, Inc.
6.9. Perosphere Pharmaceuticals, Inc.
6.10. Ferring Pharmaceuticals

List of Figures

FIG 1. Anticoagulant Reversal Drugs (ARD) Market: Research Methodology
FIG 2. ARD: Market Segmentation
FIG 3. Global ARD Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global ARD Market, by Geography, 2017 (US$ Mn)
FIG 5. Attractive Investment Proposition, by Geography, 2017
FIG 6. Competitive Analysis: Global ARD Market, by Key Players, 2017
FIG 7. Global Prothrombin Complex Concentrates (PCC) for ARD Market, 2016-2026 (US$ Mn)
FIG 8. Global Vitamin K for ARD Market, 2016-2026 (US$ Mn)
FIG 9. Global Protamine for ARD Market, 2016-2026 (US$ Mn)
FIG 10. Global Tranexmic Acid for ARD Market, 2016-2026 (US$ Mn)
FIG 11. Global Desmopressin for ARD Market, 2016-2026(US$ Mn)
FIG 12. Global Idarucizumab for ARD Market, 2016-2026(US$ Mn)
FIG 13. Global Andexxa for ARD Market, 2016-2026(US$ Mn)
FIG 14. Global Octaplex for ARD Market, (US$ Mn)
FIG 15. U.S. ARD Market, 2016-2026 (US$ Mn)
FIG 16. Canada ARD Market, 2016-2026 (US$ Mn)
FIG 17. U.K. ARD Market, 2016-2026 (US$ Mn)
FIG 18. Germany ARD Market, 2016-2026 (US$ Mn)
FIG 19. Rest of Europe ARD Market, 2016-2026 (US$ Mn)
FIG 20. China ARD Market, 2016-2026 (US$ Mn)
FIG 21. Japan ARD Market, 2016-2026 (US$ Mn)
FIG 22. Rest of Asia Pacific ARD Market, 2016-2026 (US$ Mn)
FIG 23. Brazil ARD Market, 2016-2026 (US$ Mn)
FIG 24. Mexico ARD Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Latin America ARD Market, 2016-2026 (US$ Mn)
FIG 26. GCC ARD Market, 2016-2026 (US$ Mn)
FIG 27. Rest of Middle East & Africa ARD Market, 2016-2026 (US$ Mn)

List of Tables

TABLE 1 Global Anticoagulant Reversal Drugs (ARD) Market Portraiture
TABLE 2 Global ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Phase I and II Drug for ARD Market
TABLE 4 Global ARD Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 6 North America ARD Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 7 Europe ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 8 Europe ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East & Africa ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 14 Middle East & Africa ARD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 15 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Fresenius Kabi AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Bausch Health Companies, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Amneal Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 CSL Behring Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Octapharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Portola Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Perosphere Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Ferring Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)